期刊
MOLECULAR THERAPY
卷 26, 期 1, 页码 31-44出版社
CELL PRESS
DOI: 10.1016/j.ymthe.2017.10.002
关键词
-
资金
- California Institute for Regenerative Medicine (CIRM) [TR3-05641]
- NIH [P30 CA33572]
T cell immunotherapy is emerging as a powerful strategy to treat cancer and may improve outcomes for patients with glioblastoma (GBM). We have developed a chimeric antigen receptor (CAR) T cell immunotherapy targeting IL-13 receptor alpha 2 (IL13R alpha 2) for the treatment of GBM. Here, we describe the optimization of IL13R alpha 2-targeted CAR T cells, including the design of a 4-1BB (CD137) co-stimulatory CAR (IL13BB zeta) and a manufacturing platform using enriched central memory T cells. Utilizing orthotopic human GBM models with patient-derived tumor sphere lines in NSG mice, we found that IL13BB zeta-CAR T cells improved anti-tumor activity and T cell persistence as compared to first-generation IL13 zeta-CAR CD8(+) T cells that had shown evidence for bioactivity in patients. Investigating the impact of corticosteroids, given their frequent use in the clinical management of GBM, we demonstrate that low-dose dexamethasone does not diminish CAR T cell anti-tumor activity in vivo. Furthermore, we found that local intracranial delivery of CAR T cells elicits superior anti-tumor efficacy as compared to intravenous administration, with intraventricular infusions exhibiting possible benefit over intracranial tumor infusions in a multifocal disease model. Overall, these findings help define parameters for the clinical translation of CAR T cell therapy for the treatment of brain tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据